环戊羧酸,2-氨基-4-亚甲基-,(1R,2S)-(9CI) | 32795-47-4

• 物质功能分类: 原料药 - 神经系统用药 - 抗抑郁、躁狂药
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 四氢异喹啉
• 中文名称: 环戊羧酸,2-氨基-4-亚甲基-,(1R,2S)-(9CI)
• 中文别名: 诺米芬新马来酸盐
• 英文名称: nomifensine maleate
• 英文别名: 8-amino-2-methyl-4-phenyl-1,2,3,4-tetrahydroisoquinoline maleate；1,2,3,4-tetrahydro-2-methyl-4-phenylisoquinolin-8-amine maleate；Nomifensine hydrogen maleate；nomifensine-hydrogen-maleate；Nomifensinhydrogenmaleat；(Z)-4-hydroxy-4-oxobut-2-enoate;2-methyl-4-phenyl-1,2,3,4-tetrahydroisoquinolin-2-ium-8-amine
• CAS: 32795-47-4；24524-90-1
• 化学式: C₄H₄O₄*C₁₆H₁₈N₂
• 分子量: 354.406
• InChiKey: GEOCVSMCLVIOEV-BTJKTKAUSA-N

物化性质

• 熔点：
  199-201°
• 溶解度：
  可溶于DMSO（轻微）、甲醇（轻微、加热）
• 碰撞截面：
  155.5 Ų [M+H]+ [CCS Type: TW, Method: calibrated with polyalanine and drug standards]

计算性质

• 辛醇/水分配系数(LogP)：
  2.56
• 重原子数：
  26
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  104
• 氢给体数：
  3
• 氢受体数：
  6

安全信息

• 危险等级：
  6.1(b)
• 危险品标志：
  Xn
• 安全说明：
  S26,S36
• 危险类别码：
  R22
• WGK Germany：
  3
• 包装等级：
  III
• 危险类别：
  6.1(b)
• 危险标志：
  GHS07
• 危险品运输编号：
  UN 3249
• 危险性描述：
  H302,H315,H319,H335
• 危险性防范说明：
  P261,P305 + P351 + P338

制备方法与用途

诺米芬辛（nomifensine）是一种新型抗抑郁药，适用于治疗内源性抑郁症、躁狂抑郁症和焦虑抑郁症。它主要通过抑制多巴胺转运体对人体起作用，属于4-氢异喹啉衍化的三环类化合物。诺米芬新马来酸盐的作用与三环类抗抑郁药物相似，但对心脏的抑制作用比阿米替林小。

反应信息

• 作为反应物：
  描述：

  环戊羧酸,2-氨基-4-亚甲基-,(1R,2S)-(9CI) 、 氯乙酰氯 在 sodium hydroxide 作用下， 生成 4-phenyl-8-<(chloroacetyl)amino>-2-methyl-1,2,3,4-tetrahydroisoquinoline hydrochloride
  参考文献：
  名称：

  Synthesis and pharmacological evaluation of some new tetrahydroisoquinoline derivatives inhibiting dopamine uptake and/or possessing a dopaminomimetic property

  摘要：

  As shown by structure-activity relationship studies in 8-(substituted-amino)-4-aryl-2-methyl-1,2,3,4-tetrahydroisoquinolines, the most important structural requirement for a marked antidepressant action is the presence of an ureido, (alkoxycarbonyl)amino, or [(alkylamino)acyl]amino group attached to the isoquinoline skeleton in position 8. In one of the biological tests a significant difference was found between 8-amino-4-phenyl-2-methyl-1,2,3,4-tetrahydroisoquinoline (nomifensine) and the new compounds synthesized. Nearly all compounds substituted in the amino group either decrease the spontaneous motility in mice or exert no effect on it. Two syntheses have been elaborated for the preparation of the compounds represented by the general formulas II-V where R1 = hydrogen, halogen, or methyl; Y = CONHR, OCOR, or CO(CH2)nNHR, in which R = alkyl or aralkyl or NHR = cyclic amine and n = 1-2. The syntheses start either from the corresponding 8-amino-4-aryl-2-methyl-1,2,3,4-tetrahydroisoquinolines or from the corresponding noncyclized amino alcohols. Of the compounds, 4-(p-chlorophenyl)-8-[(ethoxy-carbonyl)amino]-2-methyl-1,2,3,4- tetrahydroisoquinoline was found to possess the highest activity.

  DOI：

  10.1021/jm00157a012
• 作为产物：
  描述：

  alpha-[[[(2-氨基苯基)甲基]甲基氨基]甲基]苄醇 生成 环戊羧酸,2-氨基-4-亚甲基-,(1R,2S)-(9CI)
  参考文献：
  名称：

  NIEMINEN, K.

  摘要：

  DOI：

文献信息

• Novel Bicyclic Pyridinones
  申请人：Pettersson Martin Youngjin

  公开号：US20120252758A1

  公开（公告）日：2012-10-04

  Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I as defined herein. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

  所述化合物及其药用可接受的盐被披露，其中所述化合物具有如本文所定义的Formula I的结构。相应的药物组合物、治疗方法、合成方法和中间体也被披露。
• [EN] 6,7,8,9-TETRAHYDRO-5H-PYRIDO[2,3-d]AZEPINE DOPAMINE D3 LIGANDS<br/>[FR] LIGANDS 6,7,8,9-TÉTRAHYDRO-5H-PYRIDO[2,3-D]AZÉPINE DU RÉCEPTEUR D3 DE LA DOPAMINE
  申请人：PFIZER

  公开号：WO2017122116A1

  公开（公告）日：2017-07-20

  The present invention provides compounds of Formula (I): and pharmaceutically acceptable salts thereof wherein the variables R1, R2, R3, R4, R5, a and A are as defined herein; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating D3-mediated (or D3-associated) disorders including, e.g., substance addiction, substance abuse, schizophrenia (e.g., its cognitive symptoms), cognitive impairment (e.g., cognitive impairment associated with schizophrenia, AD or PD), Parkinson's disease, mania, anxiety, impulse control disorders, sexual disorders and depression.

  本发明提供了Formula (I)的化合物及其药学上可接受的盐，其中变量R1、R2、R3、R4、R5、a和A如本文所定义；制备方法；制备中使用的中间体；以及含有这种化合物或盐的组合物，以及它们用于治疗D3介导的（或与D3相关的）疾病，包括物质成瘾、物质滥用、精神分裂症（例如其认知症状）、认知障碍（例如与精神分裂症、阿尔茨海默病或帕金森病相关的认知障碍）、帕金森病、狂躁症、焦虑、冲动控制障碍、性功能障碍和抑郁症等疾病的用途。
• 1,1,1-TRIFLUORO-3-HYDROXYPROPAN-2-YL CARBAMATE DERIVATIVES AS MAGL INHIBITORS
  申请人：PFIZER INC.

  公开号：US20180208607A1

  公开（公告）日：2018-07-26

  The present invention provides, in part, compounds of Formula I: and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating MAGL-mediated diseases and disorders including, e.g., pain, an inflammatory disorder, depression, anxiety, Alzheimer's disease, a metabolic disorder, stroke, or cancer.

  本发明在一定程度上提供了Formula I的化合物： 及其药用盐；制备方法；制备中使用的中间体；以及含有这些化合物或盐的组合物，以及它们用于治疗MAGL介导的疾病和紊乱，包括但不限于疼痛、炎症性紊乱、抑郁症、焦虑症、阿尔茨海默病、代谢紊乱、中风或癌症。
• AMINO-HETEROCYCLIC COMPOUNDS
  申请人：Claffey Michelle M.

  公开号：US20100190771A1

  公开（公告）日：2010-07-29

  The invention provides PDE9-inhibiting compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein R 1 , R 2 , R 3 , A, and n are as defined herein. Pharmaceutical compositions containing the compounds of Formula I, and uses thereof in treating neurodegenerative and cognitive disorders, such as Alzheimer's disease and schizophrenia, are also provided.

  这项发明提供了式（I）中的PDE9抑制化合物，以及其药学上可接受的盐，其中R1、R2、R3、A和n的定义如本文所述。还提供了含有式I中化合物的药物组合物，并且提供了在治疗神经退行性和认知障碍疾病，如阿尔茨海默病和精神分裂症中的用途。
• [EN] PYRIDINE DERIVATIVES AS MUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS<br/>[FR] DÉRIVÉS DE LA PYRIDINE EN TANT QUE MODULATEURS ALLOSTÉRIQUES POSITIFS DU RÉCEPTEUR M1 MUSCARINIQUE
  申请人：PFIZER

  公开号：WO2016009297A1

  公开（公告）日：2016-01-21

  The present invention provides, in part, compounds of Formula I: (I) N-oxides thereof, and pharmaceutically acceptable salts of the compounds or N-oxides; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds,N-oxides, or salts, and their uses for treating M1-mediated (or M1-associated) disorders including, e.g., Alzheimer's disease, schizophrenia (e.g., its cognitive and negative symptoms), pain, addiction, and a sleep disorder.

  本发明部分提供了以下化合物的公式I：（I）其N-氧化物，以及该化合物或N-氧化物的药用盐；用于制备的工艺；用于制备的中间体；以及含有这些化合物、N-氧化物或盐的组合物，以及它们用于治疗M1介导（或与M1相关）疾病的用途，例如阿尔茨海默病、精神分裂症（例如其认知和消极症状）、疼痛、成瘾和睡眠障碍。